AMED and Its Role in Japan’s Pharma Investment

The Japan Agency for Medical Research and Development (AMED) is a government agency established in 2015 to centralize and streamline Japan’s national R&D efforts in the medical and life sciences fields. Modeled partly after the U.S. NIH, AMED operates under the Cabinet Office and three ministries: the Ministry of Health, Labour and Welfare (MHLW), the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and the Ministry of Economy, Trade and Industry (METI).

Purpose and Mission

AMED’s primary mission is to promote integrated, strategic R&D in medical and pharmaceutical fields, translating basic research into practical healthcare solutions. It aims to improve public health, strengthen innovation, and enhance Japan’s global competitiveness in life sciences.

Influence on Government Investment in Pharma

  1. Centralized R&D Funding
    AMED consolidates research budgets from various ministries, allocating government funds to priority projects across academia, industry, and hospitals. This reduces fragmentation and duplication, ensuring a more efficient use of public funds.
  2. Strategic Research Programs
    It runs targeted funding programs in key areas such as regenerative medicine, rare diseases, infectious diseases (e.g., COVID-19), oncology, and AI-driven drug discovery. These focus areas reflect national priorities and help shape the pharma R&D agenda.
  3. Public-Private Partnerships
    AMED facilitates collaboration between government, academia, and industry by funding consortia and joint development projects, accelerating the commercialization of innovative therapies and technologies.
  4. Global Collaboration and Standards
    AMED promotes international cooperation by participating in global health initiatives and harmonizing Japanese research standards with global practices, making it easier for Japan-based pharma innovations to reach international markets.
  5. Support for Translational Research
    A key focus of AMED is bridging the “valley of death” between basic research and clinical application. It provides funding and infrastructure for early-stage trials, regulatory support, and manufacturing scale-up—crucial areas where government investment derisks pharma development.

Impact on Pharma Sector

Through its funding and strategic guidance, AMED directly influences where Japan’s pharmaceutical innovation efforts are directed. Its programs not only fund cutting-edge science but also de-risk and accelerate the development of products with high social and economic value. For pharma companies, AMED is both a critical funding source and a policy signaler of government-backed priorities.


In summary, AMED plays a central role in aligning government investment with national health priorities, strengthening Japan’s pharmaceutical innovation ecosystem, and fostering industry-academic collaboration to translate science into healthcare impact.

Sakigake Designation: Accelerating Innovation in Japan

In the competitive world of pharmaceutical development, speed to market is crucial, especially when it comes to addressing serious diseases with unmet medical needs. Japan’s Sakigake Designation provides a powerful opportunity for developers of groundbreaking therapies, offering fast-tracked approval and enhanced support throughout the regulatory process.

Introduced in 2015 and solidified under the Pharmaceuticals and Medical Devices Act in 2020, the Sakigake Designation is designed to accelerate the development and approval of first-in-class medical products in Japan, ensuring that transformative treatments reach patients as quickly as possible.

What Is the Sakigake Designation?

The term Sakigake, meaning “pioneer” in Japanese, reflects the designation’s focus on promoting innovative treatments that lead the way in addressing serious and life-threatening conditions. Through this program, the Pharmaceuticals and Medical Devices Agency (PMDA) streamlines the approval process, cutting down timelines and supporting sponsors in bringing their therapies to market faster.

Benefits of Sakigake Designation

  1. Priority Consultation and Review
    Developers benefit from prioritized, accelerated consultation with the PMDA, allowing for clear, timely guidance on regulatory requirements and development plans. This early interaction enhances the efficiency of the entire approval process.
  2. Faster Approval Timeline
    With Sakigake Designation, a product’s review period is shortened to around 6 months, compared to the usual 12 months, giving developers a competitive edge in the fast-paced pharmaceutical market.
  3. Dedicated PMDA Support
    A dedicated PMDA concierge (case manager) is assigned to guide the sponsor through every step of the process, offering expert advice and ensuring smooth coordination between all parties involved.
  4. Extended Market Exclusivity
    Approved products are granted an additional 2 years of market exclusivity after their initial approval, giving developers extra protection to capitalize on their investment without immediate competition.

Eligibility Criteria for Sakigake Designation

Not every product qualifies for Sakigake. To be eligible, a product must:

  • Be a first-in-class therapy or demonstrate exceptional efficacy compared to existing treatments.
  • Address serious, life-threatening, or rare diseases.
  • Show significant improvement in treatment outcomes.
  • Be intended for early development and application in Japan, with Japan as a primary market.

Developer Obligations

While Sakigake offers significant benefits, there are key responsibilities for developers:

  1. Early and Continuous Engagement
    Sponsors must engage with the PMDA early and maintain an ongoing dialogue, submitting detailed development plans and regular progress updates to ensure alignment throughout the process.
  2. Robust Data Requirements
    Developers must provide comprehensive non-clinical and clinical data to support their application, even if only preliminary. This helps demonstrate the potential of the product to address unmet medical needs.
  3. Japan-First Strategy
    Products developed under Sakigake should prioritize Japan as an early market. Simultaneous or earlier regulatory submissions in other regions could affect eligibility for the designation.
  4. Post-Marketing Surveillance
    Sponsors are required to implement enhanced post-marketing surveillance and risk management strategies to monitor the long-term safety and effectiveness of their products once they are in use by patients.

Conclusion

The Sakigake Designation offers developers a unique opportunity to fast-track innovative treatments in Japan, providing faster approvalsextended market protection, and dedicated PMDA support. However, it requires a commitment to early and continuous engagement with regulatory authorities, as well as ensuring Japan remains a focal point in the product’s development strategy.

For companies looking to bring breakthrough therapies to market quickly, the Sakigake Designation is an invaluable tool for accelerating the path from innovation to patient access.


By understanding the benefits and obligations of this regulatory program, pharmaceutical companies can leverage the Sakigake Designation as a strategic advantage in bringing their life-changing therapies to Japanese patients faster.

Penetrating Japan’s Medical Device Market

Japan’s medical device market is a land of opportunity, offering a unique blend of advanced healthcare infrastructure, a rapidly aging population, and a strong appetite for innovative technologies. As the second-largest medical device market globally, Japan represents a critical destination for companies with cutting-edge products. However, entering this dynamic market requires a clear understanding of its unique trends, regulatory landscape, and customer needs.

Here’s some thoughts to unlock the potential of Japan’s medical device market—and turning challenges into opportunities.


1. Key Market Trends Driving Growth in Japan

Aging Population and Chronic Disease Burden

Japan has one of the world’s oldest populations, with nearly 30% of its citizens aged 65 or older. This demographic shift has led to a surge in demand for medical devices that address age-related conditions, such as:

  • Cardiovascular devices (e.g., pacemakers, stents)
  • Orthopedic implants (e.g., joint replacements)
  • Diabetes care devices (e.g., glucose monitors, insulin pumps)

Focus on Home Healthcare and Telemedicine

With an increasing emphasis on reducing healthcare costs and improving patient convenience, Japan is seeing rapid growth in home healthcare devices and telemedicine solutions. Products like remote monitoring devices, wearable technologies, and portable diagnostic tools are gaining traction.

Adoption of Digital Health and AI

Japan is embracing digital health technologies and AI-driven medical devices, particularly in areas like diagnostic imaging, robotic surgery, and predictive analytics. The government is actively supporting these innovations through funding and regulatory incentives.

Demand for Minimally Invasive Technologies

Japanese healthcare providers and patients alike prefer minimally invasive devices that reduce recovery times and improve outcomes. This trend is driving demand for advanced surgical tools, endoscopic devices, and catheter-based technologies.


2. Regulatory Strategy: Navigating PMDA Requirements

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) oversees the approval and regulation of medical devices. While the regulatory process can be rigorous, the PMDA is committed to fostering innovation and ensuring patient safety. Key considerations include:

  • Device Classification: Medical devices in Japan are classified into four categories (Class I to IV) based on risk. Higher-risk devices (Class III and IV) require more extensive clinical data and rigorous review.
  • Pre-Market Approval: For most devices, you’ll need to submit a Shonin application, which includes technical documentation, clinical data, and quality management system (QMS) details.
  • Post-Market Surveillance: Once approved, you must comply with Japan’s post-market requirements, including adverse event reporting and periodic safety updates.

Key Tip: Engage with the PMDA early in the development process to align your regulatory strategy with Japan’s requirements. Leveraging local regulatory consultants can streamline approvals and reduce time to market.


3. Pricing and Reimbursement: Crafting a Compelling Value Story

Japan’s National Health Insurance (NHI) system plays a significant role in the medical device market, but coverage varies depending on the type of device. Understanding how your product fits into this system is critical for market success. Here’s what you need to know:

Devices Covered Under NHI Reimbursement

Many medical devices, particularly those used in therapeutic or diagnostic procedures, are covered under NHI. Examples include:

  • Catheters (e.g., cardiovascular, urological)
  • Implantable devices (e.g., pacemakers, stents, orthopedic implants)
  • Diagnostic devices (e.g., glucose monitors, blood pressure cuffs)

For these devices, securing reimbursement is a key step. The process involves:

  • Reimbursement Application: Submit a detailed application demonstrating the clinical and economic value of your device. This includes clinical data, cost-effectiveness analyses, and evidence of improved patient outcomes.
  • Price Negotiations: Japan’s pricing environment is highly competitive, with regular price revisions. Highlighting your device’s unique benefits and cost savings can strengthen your case during negotiations.
  • Innovative Device Incentives: The government offers premium pricing and faster reimbursement pathways for innovative devices that address unmet medical needs.

Devices Purchased Through Hospital Tenders

Some medical devices, particularly high-cost capital equipment, are not covered under NHI and are purchased directly by hospitals through tenders. Examples include:

  • Imaging systems (e.g., CT scanners, MRI machines)
  • Surgical robots
  • Large laboratory equipment

For these devices, the purchasing process is driven by hospital budgets, competitive bidding, and relationships with key decision-makers. To succeed in this space:

  • Build Strong Hospital Relationships: Engage directly with hospital procurement teams and key opinion leaders (KOLs) to demonstrate the value of your product.
  • Highlight Long-Term ROI: Emphasize how your device can improve operational efficiency, reduce costs, or enhance patient outcomes over time.
  • Leverage Local Partners: Consider partnering with local distributors or agents who have established relationships with hospitals and understand the tender process.

Hybrid Models

Some devices may fall into a gray area, where certain components or procedures are reimbursed under NHI, while others are not. For example:

  • surgical robot may not be reimbursed, but the procedures performed using it may be covered.
  • Consumables used with capital equipment (e.g., biopsy needles for imaging systems) may be reimbursed, even if the equipment itself is not.

Key Tip: Work with local experts to determine how your device fits into Japan’s reimbursement and purchasing landscape. A clear understanding of the financial pathways will help you craft a compelling value story and optimize your pricing strategy.


4. Go-To-Market Strategy: Building the Right Approach

Japan’s medical device market requires a tailored go-to-market strategy that aligns with your product, resources, and long-term goals. Key options include:

Direct Market Entry

Establishing a local subsidiary allows you to maintain control over sales, marketing, and customer relationships. This approach is ideal for companies with high-value, innovative devices and a long-term commitment to Japan.

Strategic Partnerships

Partnering with local distributors or agents can accelerate market entry, especially for smaller companies or those with limited resources. However, ensure your contracts maintain your control over pricing, branding, and customer engagement.

Hybrid Models

A hybrid approach combines elements of direct market entry and partnerships. For example, you could handle regulatory approvals and marketing in-house while outsourcing distribution to a local partner.

Key Tip: Choose a strategy that balances speed to market with long-term value creation. Flexibility is key to adapting to Japan’s evolving market dynamics.


5. Customer Relationships: Building Trust in Japan

In Japan, direct relationships with healthcare providers are critical to success. To build trust and drive adoption, consider:

  • Localized Engagement: Tailor your messaging and training programs to address the specific needs of Japanese healthcare providers and patients.
  • Real-World Evidence: Collect and present data on your device’s performance in Japanese patients to strengthen your value proposition.
  • Stakeholder Collaboration: Engage with key opinion leaders (KOLs), medical societies, and policymakers to build support for your product.

Pro Tip: Invest in after-sales support and training programs to ensure your device is used effectively and to build long-term customer loyalty.


6. Long-Term Investment: Building a Sustainable Presence

Entering Japan’s medical device market is not a one-time effort—it’s a long-term commitment. Key considerations include:

  • Market Monitoring: Stay ahead of regulatory changes, reimbursement updates, and emerging healthcare trends.
  • Continuous Innovation: Japan values cutting-edge technologies. Keep your pipeline robust and explore opportunities for product enhancements or new indications.
  • Customer-Centric Approach: Continuously engage with your customers to understand their evolving needs and ensure your product remains relevant.

Why Japan? The Rewards Outweigh the Risks

While entering Japan’s medical device market is complex, the rewards are substantial. With a $30 billion market and a strong appetite for innovation, Japan offers unparalleled growth potential for companies willing to invest in a thoughtful, strategic approach. From advanced regulatory pathways to a focus on patient-centric care, Japan is a market where bold ideas can thrive.


What’s Your Strategy for Japan?

The time to act is now. Whether you’re preparing for regulatory submissions, crafting your pricing strategy, or building direct customer relationships, a well-executed plan can set you up for success in Japan’s dynamic market.

Ready to take the next step? Let’s discuss how to turn your vision into reality. Schedule a free consultation or send us a message to explore how we can help you navigate Japan’s medical device landscape with confidence.


Final Thought

Japan’s medical device market is not just a destination—it’s a gateway to global success. By understanding the unique challenges and opportunities, you can position your company for long-term growth and impact.